Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anaptysbio Inc

22.22
+1.044.91%
Post-market: 22.220.00000.00%19:15 EDT
Volume:579.85K
Turnover:12.80M
Market Cap:681.42M
PE:-4.34
High:22.52
Open:21.05
Low:21.05
Close:21.18
Loading ...

AnaptysBio Inc : UBS Cuts Target Price to $18 From $33

THOMSON REUTERS
·
13 Dec 2024

AnaptysBio Is Maintained at Overweight by Wells Fargo

Dow Jones
·
13 Dec 2024

AnaptysBio (NASDAQ:ANAB investor three-year losses grow to 55% as the stock sheds US$261m this past week

Simply Wall St.
·
13 Dec 2024

AnaptysBio Stock Down as Eczema Study Fails to Meet Goals

Zacks
·
12 Dec 2024

AnaptysBio price target lowered to $36 from $90 at Guggenheim

TIPRANKS
·
12 Dec 2024

AnaptysBio Inc : H.c. Wainwright Cuts to Neutral Rating; Cuts Target Price to $19 From $52

THOMSON REUTERS
·
12 Dec 2024

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

Benzinga
·
12 Dec 2024

AnaptysBio (ANAB) Receives a Buy from TD Cowen

TIPRANKS
·
12 Dec 2024

AnaptysBio Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
12 Dec 2024

HC Wainwright Downgrades AnaptysBio to Neutral From Buy, $19 Price Target

MT Newswires Live
·
12 Dec 2024

AnaptysBio downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
12 Dec 2024

H.C. Wainwright downgrades AnaptysBio after atopic dermatitis study disappoints

TIPRANKS
·
12 Dec 2024

BUZZ-AnaptysBio slumps after abandoning eczema drug development

Reuters
·
12 Dec 2024

AnaptysBio Inc : Wedbush Cuts Target Price to $40 From $42

THOMSON REUTERS
·
11 Dec 2024

UPDATE 2-AnaptysBio to abandon eczema drug development after mid-stage trial failure

Reuters
·
11 Dec 2024

Wedbush Cuts Price Target on AnaptysBio to $40 From $42, Maintains Outperform Rating

MT Newswires Live
·
11 Dec 2024

Is Siga Technologies (SIGA) Stock Outpacing Its Medical Peers This Year?

Zacks
·
11 Dec 2024

AnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares Fall

Dow Jones
·
11 Dec 2024

AnaptysBio Shares Fall 37.9% Premarket as Co Abandons Eczema Drug Development After Mid-Stage Trial Failure

THOMSON REUTERS
·
11 Dec 2024

AnaptysBio Says Phase 2B Trial in Atopic Dermatitis Failed to Meet Endpoints

MT Newswires Live
·
11 Dec 2024